Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2018 | Improving outcomes for R/R DLBCL with polatuzumab vedotin

Marek Trněný • 14 Jun 2018
EHA 2018
B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Antibodies Bendamustine Polatuzumab vedotin Rituximab
NiHiL

Patients with relapsed, transplant ineligible diffuse large B-cell lymphoma (DLBCL) face extremely poor outcomes. In this video, recorded at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, Marek Trněný, MD, PhD, of Charles University, Prague, Czech Republic, discusses a recent trial (NCT02257567) that aimed to improve care for these patients using a combination therapy of bendamustine, rituximab and the antibody-drug conjugate polatuzumab vedotin. The positive survival data from this study suggest a new treatment avenue for patients who previously had few options.

More from Marek Trněný

Evolving treatment landscape of MCL
John Kuruvilla et al. • 17 Oct 2023
1:59
Rituximab maintenance key to outcome improvement in mantle cell lymphoma
Marek Trněný • 14 Jun 2018
3:12
Prognostic indices for follicular lymphoma: PRIMA-PI
Marek Trněný • 14 Jun 2018
2:09
iwNHL 2017 highlights: the PDX model
Marek Trněný • 8 Sep 2017

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals